Source: globenewswire.com
MacroGenics Inc. has announced positive results from SOPHIA, a Phase 3 clinical study of margetuximab in HER2-positive metastatic breast cancer patients. Margetuximab is an investigational immune-enhancing monoclonal antibody derived from the Company’s proprietary Fc Optimization technology platform. MacroGenics anticipates submitting a Biologics License Application (BLA) to the U.S. Food and Drug Administration in the second half of 2019. Following this news announcement, shares of MacroGenics surged almost ~100% to trade at a market capitalization of $966.5 million.
